EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Bruce E. Sands  1     Krisztina Barbara Gecse  2     David T. Rubin  3     Yvette Leung  4     Julian Panés  5     Martina Goetsch  6     Wenjin Wang  7     Kevin Shan  8     John C. Woolcott  7     Christina Smith  7     Karolina Wosik  9     Stefan Schreiber  10    
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 Amsterdam University Medical Center, Amsterdam, Netherlands
3 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
4 University of British Columbia, Vancouver, Canada
5 Formerly of Hospital Clínic Barcelona, IDIBAPS, CIBRehd, Barcelona, Spain
6 Pfizer AG, Zürich, Switzerland
7 Pfizer Inc, Collegeville, United States
8 Pfizer Inc, New York, United States
9 Pfizer Inc, Kirkland, Canada
10 University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing